The evaluation of the metabolic and autonomic predictors of cardiovascular diseases in relation to prostatic hyperplasia symptoms

Bratisl Lek Listy. 2022;123(10):740-744. doi: 10.4149/BLL_2022_119.

Abstract

Objectives: High prevalence of cardiovascular diseases is present in benign prostatic hyperplasia patients. Risk prediction models were developed for early identification of these cardiovascular risks. We aimed to evaluate cardiovascular metabolic and autonomic predictors in relation to lower urinary tract symptoms' severity evaluated by the IPSS score.

Methods: This study included 318 healthy individuals recently diagnosed with BPH. Laboratory tests including metabolic, hormonal and inflammatory markers were recorded. The cardiovascular risk indices like the atherogenic index of plasma and the triglyceride glucose index were calculated. The heart rate recovery after graded exercise was calculated.

Results: There was a significant positive correlation between the IPSS score and both the atherogenic and the triglyceride glucose indices (r = 0.388, p < 0.01 and r = 0.109, p = 0.032, respectively). IPSS score was also significantly negatively correlated with heart rate recovery specially at the 3rd minute after exercise (r = -0.547, p < 0.01). On the other hand, the IPSS score had a significant positive correlation with the inflammatory markers and a significant negative correlation with serum testosterone levels.

Conclusions: Our study results suggest the presence of a combination of hormonal and inflammatory changes in BPH patients affecting the severity of LUTS which is correlated with metabolic and autonomic parameters that can predict an increased risk of CVD (Tab. 3, Ref. 47).

Keywords: atherogenic index of plasma; benign prostatic hyperplasia; triglyceride glucose index heart rate recovery..

MeSH terms

  • Biomarkers
  • Cardiovascular Diseases* / complications
  • Glucose
  • Humans
  • Lower Urinary Tract Symptoms* / epidemiology
  • Lower Urinary Tract Symptoms* / etiology
  • Male
  • Prostatic Hyperplasia* / complications
  • Prostatic Hyperplasia* / diagnosis
  • Triglycerides

Substances

  • Biomarkers
  • Triglycerides
  • Glucose